Growth inhibition of imatinib-resistant CML cells with the T315I mutation and hypoxia-adaptation by AV65 - a novel Wnt/β-catenin signaling inhibitor

Cancer Letters

Volumn 312, Issue 1, 2011, Pages 91-100

  Nagao, Rina ^a   Ashihara, Eishi ^a,b   Kimura, Shinya ^c   Strovel, Jeffrey W ^d   Yao, Hisayuki ^a   Takeuchi, Miki ^a   Tanaka, Ruriko ^a   Hayashi, Yoshihiro ^a   Hirai, Hideyo ^a   Padia, Janak ^d   Strand, Kathryn ^d   Maekawa, Taira ^a  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^c SAGA UNIVERSITY   (Japan)

^d PGx Health   (United States)

Author keywords

Catenin; CML; Hypoxia adaptation; Imatinib resistance; T315I

Indexed keywords

AV 65; BCR ABL PROTEIN; BETA ACTIN; BETA CATENIN; CYCLIN D1; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MYC PROTEIN; PROTEIN INHIBITOR; PROTEIN KINASE B; STAT5 PROTEIN; SURVIVIN; UNCLASSIFIED DRUG; WNT PROTEIN;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL HYPOXIA; CELL PROLIFERATION; CHEMOSENSITIVITY; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG POTENTIATION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; INHIBITION KINETICS; LEUKEMIA CELL; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BETA CATENIN; CELL GROWTH PROCESSES; CELL HYPOXIA; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; G1 PHASE; HUMANS; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MUTATION; PIPERAZINES; PYRIMIDINES; S PHASE; WNT PROTEINS; WNT SIGNALING PATHWAY;

EID: 80053339429     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.08.002     Document Type: Article

References (51)

1. Sawyers C.L. Chronic myeloid leukemia. N. Engl. J. Med. 1999, 340:1330-1340.
2. Goldman J.M., Melo J.V. Chronic myeloid leukemia - advances in biology and new approaches to treatment. N. Engl. J. Med. 2003, 349:1451-1464.
3. Druker B.J., Guilhot F., O'Brien S.G., Gathmann I., Kantarjian H., Gattermann N., Deininger M.W., Silver R.T., Goldman J.M., Stone R.M., Cervantes F., Hochhaus A., Powell B.L., Gabrilove J.L., Rousselot P., Reiffers J., Cornelissen J.J., Hughes T., Agis H., Fischer T., Verhoef G., Shepherd J., Saglio G., Gratwohl A., Nielsen J.L., Radich J.P., Simonsson B., Taylor K., Baccarani M., So C., Letvak L., Larson R.A. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 2006, 355:2408-2417.
4. Hochhaus A., La Rosee P. Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia 2004, 18:1321-1331.
5. Kantarjian H., Shah N.P., Hochhaus A., Cortes J., Shah S., Ayala M., Moiraghi B., Shen Z., Mayer J., Pasquini R., Nakamae H., Huguet F., Boque C., Chuah C., Bleickardt E., Bradley-Garelik M.B., Zhu C., Szatrowski T., Shapiro D., Baccarani M. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 2010, 362:2260-2270.
6. Saglio G., Kim D.W., Issaragrisil S., Le Coutre P., Etienne G., Lobo C., Pasquini R., Clark R.E., Hochhaus A., Hughes T.P., Gallagher N., Hoenekopp A., Dong M., Haque A., Larson R.A., Kantarjian H.M. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N. Engl. J. Med. 2010, 362:2251-2259.
7. Puttini M., Coluccia A.M., Boschelli F., Cleris L., Marchesi E., Donella-Deana A., Ahmed S., Redaelli S., Piazza R., Magistroni V., Andreoni F., Scapozza L., Formelli F., Gambacorti-Passerini C. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res. 2006, 66:11314-11322.
8. Kimura S., Naito H., Segawa H., Kuroda J., Yuasa T., Sato K., Yokota A., Kamitsuji Y., Kawata E., Ashihara E., Nakaya Y., Naruoka H., Wakayama T., Nasu K., Asaki T., Niwa T., Hirabayashi K., Maekawa T. NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood 2005, 106:3948-3954.
9. Deguchi Y., Kimura S., Ashihara E., Niwa T., Hodohara K., Fujiyama Y., Maekawa T. Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines. Leuk. Res. 2008, 2:980-983.
10. Tanaka R., Kimura S. Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation. Expert. Rev. Anticancer Ther. 2008, 8:1387-1398.
11. Michor F., Hughes T.P., Iwasa Y., Branford S., Shah N.P., Sawyers C.L., Nowak M.A. Dynamics of chronic myeloid leukaemia. Nature 2005, 435:1267-1270.
12. Copland M., Hamilton A., Elrick L.J., Baird J.W., Allan E.K., Jordanides N., Barow M., Mountford J.C., Holyoake T.L. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 2006, 107:4532-4539.
13. Jamieson C.H., Ailles L.E., Dylla S.J., Muijtjens M., Jones C., Zehnder J.L., Gotlib J., Li K., Manz M.G., Keating A., Sawyers C.L., Weissman I.L. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N. Engl. J. Med. 2004, 351:657-667.
14. Radich J.P., Dai H., Mao M., Oehler V., Schelter J., Druker B., Sawyers C., Shah N., Stock W., Willman C.L., Friend S., Linsley P.S. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc. Natl. Acad. Sci. USA 2006, 103:2794-2799.
15. McWeeney S.K., Pemberton L.C., Loriaux M.M., Vartanian K., Willis S.G., Yochum G., Wilmot B., Turpaz Y., Pillai R., Druker B.J., Snead J.L., MacPartlin M., O'Brien S.G., Melo J.V., Lange T., Harrington C.A., Deininger M.W. A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib. Blood 2010, 115:315-325.
16. Zhao C., Blum J., Chen A., Kwon H.Y., Jung S.H., Cook J.M., Lagoo A., Reya T. Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell 2007, 12:528-541.
17. Coluccia A.M., Vacca A., Dunach M., Mologni L., Redaelli S., Bustos V.H., Benati D., Pinna L.A., Gambacorti-Passerini C. Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation. EMBO J. 2007, 26:1456-1466.
18. Katoh M., Katoh M. WNT signaling pathway and stem cell signaling network. Clin. Cancer Res. 2007, 13:4042-4045.
19. Ysebaert L., Chicanne G., Demur C., De Toni F., Prade-Houdellier N., Ruidavets J.B., Mansat-De Mas V., Rigal-Huguet F., Laurent G., Payrastre B., Manenti S., Racaud-Sultan C. Expression of beta-catenin by acute myeloid leukemia cells predicts enhanced clonogenic capacities and poor prognosis. Leukemia 2006, 20:1211-1216.
20. Wu Q.L., Zierold C., Ranheim E.A. Dysregulation of Frizzled 6 is a critical component of B-cell leukemogenesis in a mouse model of chronic lymphocytic leukemia. Blood 2009, 113:3031-3039.
21. Strand K.J., Khalak H., Strovel J.W., Ebner R., Augustus M. Expression biomarkers for clinical efficacy and outcome prediction in cancer. Pharmacogenomics 2006, 7:105-115.
22. Bol D., Ebner R. Gene expression profiling in the discovery, optimization and development of novel drugs: one universal screening platform. Pharmacogenomics 2006, 7:227-235.
23. Ito T., Tanaka H., Kimura A. Establishment and characterization of a novel imatinib-sensitive chronic myeloid leukemia cell line MYL, and an imatinib-resistant subline MYL-R showing overexpression of Lyn. Eur. J. Haematol. 2007, 78:417-431.
24. Yanagisawa K., Yamauchi H., Kaneko M., Kohno H., Hasegawa H., Fujita S. Suppression of cell proliferation and the expression of a bcr-abl fusion gene and apoptotic cell death in a new human chronic myelogenous leukemia cell line, KT-1, by interferon-alpha. Blood 1998, 91:641-648.
25. Beran M., Pisa P., O'Brien S., Kurzrock R., Siciliano M., Cork A., Andersson B.S., Kohli V., Kantarjian H. Biological properties and growth in SCID mice of a new myelogenous leukemia cell line (KBM-5) derived from chronic myelogenous leukemia cells in the blastic phase. Cancer Res. 1993, 53:3603-3610.
26. Zhang H., Trachootham D., Lu W., Carew J., Giles F.J., Keating M.J., Arlinghaus R.B., Huang P. Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism. Leukemia 2008, 22:1191-1199.
27. Takeuchi M., Kimura S., Kuroda J., Ashihara E., Kawatani M., Osada H., Umezawa K., Yasui E., Imoto M., Tsuruo T., Yokota A., Tanaka R., Nagao R., Nakahata T., Fujiyama Y., Maekawa T. Glyoxalase-I is a novel target against Bcr-Abl+ leukemic cells acquiring stem-like characteristics in a hypoxic environment. Cell Death. Differ. 2010, 17:1211-1220.
28. Takeuchi M., Ashihara E., Yamazaki Y., Kimura S., Nakagawa Y., Tanaka R., Yao H., Nagao R., Hayashi Y., Hirai H., Maekawa T. Rakicidin A effectively induces apoptosis in hypoxia adapted Bcr-Abl positive leukemic cells. Cancer Sci. 2011, 102:591-596.
29. Kamitsuji Y., Kuroda J., Kimura S., Toyokuni S., Watanabe K., Ashihara E., Tanaka H., Yui Y., Watanabe M., Matsubara H., Mizushima Y., Hiraumi Y., Kawata E., Yoshikawa T., Maekawa T., Nakahata T., Adachi S. The Bcr-Abl kinase inhibitor INNO-406 induces autophagy and different modes of cell death execution in Bcr-Abl-positive leukemias. Cell Death. Differ. 2008, 15:1712-1722.
30. Kawata E., Ashihara E., Nakagawa Y., Kiuchi T., Ogura M., Yao H., Sakai K., Tanaka R., Nagao R., Yokota A., Takeuchi M., Kimura S., Hirai H., Maekawa T. A combination of a DNA-chimera siRNA against PLK-1 and zoledronic acid suppresses the growth of malignant mesothelioma cells in vitro. Cancer Lett. 2010, 294:245-253.
31. Kimura S., Kuroda J., Segawa H., Sato K., Nogawa M., Yuasa T., Ottmann O.G., Maekawa T. Antiproliferative efficacy of the third-generation bisphosphonate, zoledronic acid, combined with other anticancer drugs in leukemic cell lines. Int. J. Hematol. 2004, 79:37-43.
32. Ashihara E., Kawata E., Nakagawa Y., Shimazaski C., Kuroda J., Taniguchi K., Uchiyama H., Tanaka R., Yokota A., Takeuchi M., Kamitsuji Y., Inaba T., Taniwaki M., Kimura S., Maekawa T. Beta-catenin small interfering RNA successfully suppressed progression of multiple myeloma in a mouse model. Clin. Cancer Res. 2009, 15:2731-2738.
33. Kimura S., Maekawa T., Hirakawa K., Murakami A., Abe T. Alterations of c-myc expression by antisense oligodeoxynucleotides enhance the induction of apoptosis in HL-60 cells. Cancer Res. 1995, 55:1379-1384.
34. Kubonishi I., Miyoshi I. Establishment of a Ph1 chromosome-positive cell line from chronic myelogenous leukemia in blast crisis. Int. J. Cell Cloning 1983, 1:105-117.
35. Abrahamsson A.E., Geron I., Gotlib J., Dao K.H., Barroga C.F., Newton I.G., Giles F.J., Durocher J., Creusot R.S., Karimi M., Jones C., Zehnder J.L., Keating A., Negrin R.S., Weissman I.L., Jamieson C.H. Glycogen synthase kinase 3beta missplicing contributes to leukemia stem cell generation. Proc. Natl. Acad. Sci. USA 2009, 106:3925-3929.
36. Polakis P. The many ways of Wnt in cancer. Curr. Opin. Genet. Dev. 2007, 17:45-51.
37. Aberle H., Bauer A., Stappert J., Kispert A., Kemler R. Beta-catenin is a target for the ubiquitin-proteasome pathway. EMBO J. 1997, 16:3797-3804.
38. Dihlmann S., von Knebel Doeberitz M. Wnt/beta-catenin-pathway as a molecular target for future anti-cancer therapeutics. Int. J. Cancer 2005, 113:515-524.
39. Lepourcelet M., Chen Y.N., France D.S., Wang H., Crews P., Petersen F., Bruseo C., Wood A.W., Shivdasani R.A. Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex. Cancer Cell 2004, 5:91-102.
40. Yao H., Ashihara E., Maekawa T. Targeting the Wnt/beta-catenin signaling pathway in human cancers. Expert Opin. Ther. Targets 2011, 15:87.
41. Sengupta A., Banerjee D., Chandra S., Banerji S.K., Ghosh R., Roy R., Banerjee S. Deregulation and cross talk among Sonic hedgehog, Wnt, Hox and Notch signaling in chronic myeloid leukemia progression. Leukemia 2007, 21:949-955.
42. Bradeen H.A., Eide C.A., O'Hare T., Johnson K.J., Willis S.G., Lee F.Y., Druker B.J., Deininger M.W. Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood 2006, 108:2332-2338.
43. Soverini S., Colarossi S., Gnani A., Rosti G., Castagnetti F., Poerio A., Iacobucci I., Amabile M., Abruzzese E., Orlandi E., Radaelli F., Ciccone F., Tiribelli M., di Lorenzo R., Caracciolo C., Izzo B., Pane F., Saglio G., Baccarani M., Martinelli G. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA working party on chronic myeloid leukemia. Clin. Cancer Res. 2006, 12:7374-7379.
44. Nicolini F.E., Hayette S., Corm S., Bachy E., Bories D., Tulliez M., Guilhot F., Legros L., Maloisel F., Kiladjian J.J., Mahon F.X., Le Q.H., Michallet M., Roche-Lestienne C., Preudhomme C. Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation. Haematologica 2007, 92:1238-1241.
45. Tanaka R., Squires M.S., Kimura S., Yokota A., Nagao R., Yamauchi T., Takeuchi M., Yao H., Reule M., Smyth T., Lyons J.F., Thompson N.T., Ashihara E., Ottmann O.G., Maekawa T. Activity of the multi-targeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL positive leukemic cells. Blood 2010, 116:2089-2095.
46. Shiotsu Y., Kiyoi H., Ishikawa Y., Tanizaki R., Shimizu M., Umehara H., Ishii K., Mori Y., Ozeki K., Minami Y., Abe A., Maeda H., Akiyama T., Kanda Y., Sato Y., Akinaga S., Naoe T. KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation,. Blood 2009, 114:1607-1617.
47. Akahane D., Tauchi T., Okabe S., Nunoda K., Ohyashiki K. Activity of a novel Aurora kinase inhibitor against the T315I mutant form of BCR-ABL: in vitro and in vivo studies. Cancer Sci. 2008, 99:1251-1257.
48. Ninomiya M., Abe A., Katsumi A., Xu J., Ito M., Arai F., Suda T., Ito M., Kiyoi H., Kinoshita T., Naoe T. Homing, proliferation and survival sites of human leukemia cells in vivo in immunodeficient mice. Leukemia 2007, 21:136-142.
49. Ishikawa F., Yoshida S., Saito Y., Hijikata A., Kitamura H., Tanaka S., Nakamura R., Tanaka T., Tomiyama H., Saito N., Fukata M., Miyamoto T., Lyons B., Ohshima K., Uchida N., Taniguchi S., Ohara O., Akashi K., Harada M., Shultz L.D. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat. Biotechnol. 2007, 25:1315-1321.
50. Desplat V., Faucher J.L., Mahon F.X., Dello Sbarba P., Praloran V., Ivanovic Z. Hypoxia modifies proliferation and differentiation of CD34(+) CML cells. Stem Cells 2002, 20:347-354.
51. Giuntoli S., Rovida E., Barbetti V., Cipolleschi M.G., Olivotto M., Dello Sbarba P. Hypoxia suppresses BCR/Abl and selects imatinib-insensitive progenitors within clonal CML populations. Leukemia 2006, 20:1291-1293.